Integrated Biopharma, Inc.
INBP
$0.3069
$0.01194.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.60% | 5.44% | -1.91% | 0.37% | -6.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.60% | 5.44% | -1.91% | 0.37% | -6.08% |
| Cost of Revenue | 4.13% | 1.35% | -4.55% | -1.58% | -1.74% |
| Gross Profit | 125.19% | 64.78% | 30.22% | 23.81% | -51.40% |
| SG&A Expenses | -0.31% | -0.56% | -2.76% | -7.37% | -11.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.77% | 1.22% | -4.42% | -2.01% | -2.65% |
| Operating Income | 144.69% | 1,007.41% | 408.86% | 706.82% | -1,269.70% |
| Income Before Tax | 140.93% | 1,195.65% | 398.80% | 665.22% | -904.44% |
| Income Tax Expenses | 198.57% | 1,784.62% | 239.53% | 123.33% | -800.00% |
| Earnings from Continuing Operations | 130.37% | 538.98% | 570.00% | 1,681.25% | -594.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 130.37% | 538.98% | 570.00% | 1,681.25% | -594.55% |
| EBIT | 144.69% | 1,007.41% | 408.86% | 706.82% | -1,269.70% |
| EBITDA | 176.20% | 2,413.04% | 200.00% | 232.31% | -723.33% |
| EPS Basic | 129.92% | 530.00% | 584.62% | 1,800.00% | -605.56% |
| Normalized Basic EPS | 147.31% | 1,150.00% | 405.88% | 630.00% | -933.33% |
| EPS Diluted | 129.13% | 530.00% | 584.62% | 1,800.00% | -605.56% |
| Normalized Diluted EPS | 146.24% | 1,130.00% | 394.12% | 700.00% | -933.33% |
| Average Basic Shares Outstanding | 0.25% | 0.45% | 0.50% | 0.50% | 0.50% |
| Average Diluted Shares Outstanding | 4.00% | 2.28% | -2.12% | -2.22% | 0.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
